)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
MediciNova
MediciNova (MNOV) investor relations material
MediciNova Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Development focus remains MN-166 (ibudilast) across neurological and other disorders, and MN-001 (tipelukast) for fibrotic and metabolic diseases.
Q3 net loss narrowed YoY as R&D spending fell; cash was $29.3M at quarter-end, with management expecting funding through at least March 2028.
Financial highlights
Q3 2026 revenue was $138,555 vs. $123,319; operating loss was $3.06M vs. $3.38M, and net loss was $2.84M vs. $3.05M.
Q3 basic and diluted net loss per share was $0.06, unchanged YoY.
9M 2026 revenue was $783,978 vs. $257,918; operating loss was $8.44M vs. $10.19M, and net loss was $7.74M vs. $9.20M.
9M R&D and patent expense declined to $3.54M from $5.61M; G&A increased to $5.29M from $4.61M.
Outlook and guidance
Management expects to maintain R&D costs through the remainder of 2026 as development programs progress, and expects operating losses for the next several years.
Management believes working capital is sufficient to fund operations through at least March 2028, but cannot assure resources will fund all programs as planned.
Development strategy includes grant-funded and investigator-sponsored trials, non-dilutive financing, and seeking strategic alliances for clinical development and commercialization.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MediciNova
- Key clinical data from ALS and metabolic trials expected soon, with cash runway secured.MNOV
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027.MNOVQ2 2026
- Pivotal ALS and metabolic trials advance with strong funding and key data expected in 2026.MNOVCorporate presentation
- 2024 net loss increased to $11.0 million, with no product revenue and higher R&D expenses.MNOVQ4 2024
- Plans to raise up to $300M for clinical development of novel therapies in high-need areas.MNOVRegistration filing
- Q3 2024 net loss widened to $2.85 million as R&D costs rose and cash reserves fell to $42.3 million.MNOVQ3 2024
- Q1 2025 net loss was $2.86 million, with $36.6 million in cash and stable operating expenses.MNOVQ1 2025
- Annual meeting to vote on director, auditor, executive pay, and say-on-pay frequency; board favors 3 years.MNOVProxy filing
- Cash position supports operations through 2025 as net loss narrows and clinical programs advance.MNOVQ2 2024
Next MediciNova earnings date
Q4 202612 Feb, 2027
MediciNova
Next MediciNova earnings date
Q4 202612 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)